First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients

Bibliography

• GLOBOCAN 2008. International Agency for Research on Cancer. Available from: http://globocan.iarc.fr/factsheet.asp [Last accessed 2 May 2012]
   Google Scholar
• Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909
   PubMed Web of Science ®Google Scholar
• Cullen MH, Billingham LJ, Woodroffe CM, Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999;17:3188-94
   PubMed Web of Science ®Google Scholar
• Pallares C, Maroto P, Andres L, Relationship between quality of life and clinical outcome in advanced non-small cell lung cancer: prospective randomized trial of best supportive care versus best supportive care plus chemotherapy [ESMO Meeting Proceedings, abstr 426]. Ann Oncol 1996;7:89
   PubMedGoogle Scholar
• Kosmidis P. Chemotherapy in NSCLC: historical review. Lung Cancer 2002;38(Suppl 3):S19-22
   Google Scholar
• Bunn PA Jr. Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why? J Clin Oncol 2002;20:23-33
   Google Scholar
• NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008;26:4617-25
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani CP, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8
   PubMed Web of Science ®Google Scholar
• Kelly K, Crowley J, Bunn PA Jr, Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non–small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001;19:3210-18
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, De Marinis F, Rinaldi M, Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285-91
   PubMed Web of Science ®Google Scholar
• Rajeswaran A, Trojan A, Burnand B, Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer 2008;59:1-11
   PubMed Web of Science ®Google Scholar
• Carney DN. Lung cancer–time to move on from chemotherapy. N Engl J Med 2002;346:126-8
   PubMed Web of Science ®Google Scholar
• Hirsh V. Systemic therapies in metastatic non-small-cell lung cancer with emphasis on targeted therapies: the rational approach. Curr Oncol 2010;17:13-23
   PubMed Web of Science ®Google Scholar
• Neal JW. Histology matters: individualizing treatment in non-small cell lung cancer. Oncologist 2010;15:3-5
   PubMed Web of Science ®Google Scholar
• Socinski MA. The emerging role of biomarkers in advanced non-small-cell lung cancer. Clin Lung Cancer 2010;11:149-59
   PubMed Web of Science ®Google Scholar
• Coate LE, Shepherd FA. Maintenance therapy in advanced non-small cell lung cancer. J Thorac Oncol 2010;5:723-34
   PubMedGoogle Scholar
• Herbst RS, Lynch TJ, Sandler AB. Beyond doublet chemotherapy for advanced non–small-cell lung cancer: combination of targeted agents with first-line chemotherapy. Clin Lung Cancer 2009;10:20-7
   PubMed Web of Science ®Google Scholar
• Horn L, Sandler A. Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer. Clin Cancer Res 2009;15:5040-8
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues PJ, Ciuleanu T, Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32
   PubMed Web of Science ®Google Scholar
• Maemondo M, Inoue A, Kobayashi K, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8
   PubMed Web of Science ®Google Scholar
• Rosell R, Moran T, Queralt C, Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-67
   PubMed Web of Science ®Google Scholar
• Yuan A, Yu CJ, Kuo SH, Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol 2001;19:432-41
   PubMed Web of Science ®Google Scholar
• Shimanuki Y, Takahashi K, Cui R, Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer. Lung 2005;183:29-42
   PubMed Web of Science ®Google Scholar
• Kaya A, Ciledag A, Gulbay BE, The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients. Respir Med 2004;98:632-6
   PubMed Web of Science ®Google Scholar
• Han H, Silverman JF, Santucci TS, Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol 2001;8:72-9
   PubMed Web of Science ®Google Scholar
• Fontanini G, Faviana P, Lucchi M, A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br J Cancer 2002;86:558-63
   PubMed Web of Science ®Google Scholar
• Ishii H, Yazawa T, Sato H, Enhancement of pleural dissemination and lymph node metastasis of intrathoracic lung cancer cells by vascular endothelial growth factors (VEGFs). Lung Cancer 2004;45:325-37
   PubMed Web of Science ®Google Scholar
• Savai R, Langheinrich AC, Schermuly RT, Evaluation of angiogenesis using micro-computed tomography in a xenograft mouse model of lung cancer. Neoplasia 2009;11:48-56
   PubMed Web of Science ®Google Scholar
• Takayama K, Ueno H, Nakanishi Y, Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res 2000;60(8):2169-77
   PubMed Web of Science ®Google Scholar
• Kabbinavar FF, Wong JT, Ayala RE, The effect of antibody to vascular endothelial growth factor and cisplatin on the growth of lung tumors in nude mice [abstract 2906]. Proc Am Assoc Cancer Res 1995;36:488
   Google Scholar
• Horn L, Sandler AB. Angiogenesis in the treatment of non–small cell lung cancer. Proc Am Thorac Soc 2009;6:206-17
   PubMedGoogle Scholar
• Sandler A, Gray R, Perry MC, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatloukal P, Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009;27:1227-34
   PubMed Web of Science ®Google Scholar
• Wozniak AJ, Crowley JJ, Balcerzak SP, Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1998;16:2459-65
   PubMed Web of Science ®Google Scholar
• Available from: http://clinicaltrials.gov/ct2/show/NCT00620971 [Last accessed 25 August 2010]
   Google Scholar
• Burstein HJ, Chen HY, Parker LM, VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res 2008;14:7871-7
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatloukal P, Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010;21:1804-9
   PubMed Web of Science ®Google Scholar
• Ohe Y, Ohashi Y, Kubota K, Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-Arm Cooperative Study in Japan. Ann Oncol 2007;18:317-23
   PubMed Web of Science ®Google Scholar
• Souquet PJ, Tan EH, Rodrigues PJ, GLOB-1: a prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small-cell lung cancer patients. Ann Oncol 2002;13:1853-61
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62
   PubMed Web of Science ®Google Scholar
• Patel JD, Hensing TA, Rademaker A, Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 2009;27:3284-9
   PubMed Web of Science ®Google Scholar
• Hunsberger S, Zhao Y, Simon R. Comparison of Phase II Study Strategies. Clin Cancer Res 2009;15:5950-5
   PubMed Web of Science ®Google Scholar
• Das M, Wakelee H. Targeting VEGF in lung cancer. Expert Opin Ther Targets 2012;16:395-406
   PubMed Web of Science ®Google Scholar